OpenEvidence has considered raising $200 million at a $20 billion valuation but is unlikely to move forward with the round, The Information reported July 17.
A source involved in the discussions told the news outlet the deal would dilute shares held by founders and existing investors. That same source said OpenEvidence has held acquisition talks with a large technology company in the past several months.
The AI-powered clinical reference platform is now generating roughly $300 million in annualized revenue, or about $25 million a month — double what it was bringing in seven months earlier, when the company was in talks to raise at a $12 billion valuation, according to the July 17 story. OpenEvidence closed that $250 million series D round, led by Thrive Capital and DST Global, in January.
OpenEvidence, which trains its models on peer-reviewed medical literature rather than open internet data, says it is used by more than 860,000 licensed U.S. clinicians and is running at roughly breakeven on a cash-flow basis.
Founded in 2022, OpenEvidence has raised about $700 million over the past year and counts New York City-based Mount Sinai Health System, Los Angeles-based Cedars-Sinai and Sacramento, Calif.-based Sutter Health among the health systems that have integrated the tool into clinical workflows.
Editor’s note: Becker’s reached out to OpenEvidence for comment and will update the story if the company responds.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
